Oricell Therapeutics Presented at 43rd Annual J.P. Morgan Healthcare Conference

Shanghai, China & New Jersey, USA (21 January, 2025) – Oricell Therapeutics (Oricell), a clinical-stage biotech company at the forefront of oncology immunotherapy and advanced cell therapy development, announced the successful presentation at the 43rd Annual J.P. Morgan Healthcare Conference held at the Westin St. Francis in San Francisco, California. This is the second consecutive year that Oricell presented at J.P. Morgan Healthcare Conference.

Oricell’s newly onboarded president, Tom Farrell, presented Oricell’s proprietary platform, pipeline?progress, global footprint and ambition. Oricell’s lead program in Multiple Myeloma franchise, OriCAR-017, a GPRC5D targeted CAR-T, continues to show best-in-class potential in the clinic amongst same target therapies globally. Oricell’s lead program in solid tumor franchise, OriC-101, also delivers best-in-class data and potentially breakthrough level of efficacy and durability to HCC patients worldwide. The presentation sets a good start for 2025 which marks a milestone year for Oricell to advance its clinical development of OriCAR-017 in the U.S. and accelerate multiple next-generation CAR-Ts into the clinic in China.

About Oricell Therapeutics

Oricell is a clinical-stage biotechnology company dedicated to developing innovative cell therapies to address unmet medical needs in oncology and immunology around the world. With Ori?Ab, Ori?CAR technology platforms, and unique CMC know-how, Oricell has developed a broad portfolio of pipeline programs for the treatment of hematologic malignancies and solid tumors. These therapies have demonstrated well-tolerated?and substantial efficacy in exploratory clinical studies. The related clinical results were presented at international conferences and published in international academic journals, including the 2021 ASCO, 2022 ASCO, 2022 EHA, 2024 ASCO, 2024 SITC, 2024 ASH and The Lancet Haematology.

Forward-Looking Statements

This press release contains “forward-looking statements” which are not historical facts, but instead are predictions about future events based on the beliefs as well as assumptions made by and information currently available to the management of Oricell Therapeutics Holdings Limited (the “Company” or “Oricell”). The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Company, or industry results, to differ materially from any future results, performance or achievement implied by such forward-looking statements. Any forward-looking statements contained in this press release speak only as of the date of this press release. The Company assumes no obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.